{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-001322","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.225039+00:00","generated_at":"2026-06-04T22:40:49.440014+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anika Q4 revenue $43.0M (+8%), net loss incl. $62.2M impairment; guides FY2024 adj. EBITDA $25-30M","bullets":["Q4 revenue $43.0M (+8% YoY); net loss ($63.0M) or ($4.30)/share due to $62.2M non-cash impairment on Arthrosurface/Parcus intangibles.","FY2023 revenue $166.7M (+7% YoY); OA Pain Management record $101.9M (+11%).","Announces ~9% workforce reduction expected to save ~$10 million annually in 2024.","FY2024 guidance: revenue $168-173M (+1-4%), adj. EBITDA $25-30M (margin at least 15%), up >75% at midpoint.","Engaged Piper Sandler for strategic review, evaluating alternatives including potential sale."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-001322","json":"https://secwatch.observer/filing/0001171843-24-001322.json","markdown":"https://secwatch.observer/filing/0001171843-24-001322.md","text":"https://secwatch.observer/filing/0001171843-24-001322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001322/0001171843-24-001322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001322/f8k_031324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:40:49.440014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"181a4869debda0381f8979dd49504fc0693988af","claim":"Anika Therapeutics, Inc. reported fiscal year ended December 31, 2023 results: revenue $166.7 million, net income ($82.7) million, EPS ($5.64) per share. Guidance initiated.","evidence_excerpt":"Revenue for fiscal 2023 increased 7% to $166.7 million, compared with $156.2 million in 2022. OA Pain Management revenue of $101.9 million, up 11% Joint Preservation and Restoration revenue of $54.9 million, up 9% Non-Orthopedic revenue of $9.9 million, down 29% Gross margin was 62%, including $6.2 million of non-cash acquisition-related intangible asset amortization and $0.7 million of product rationalization charges. Adjusted gross margin 1 , excluding these charges, was 66%. Including the fourth quarter non-cash impairment charge, net loss was ($82.7) million, or ($5.64) per share, compared to net loss of ($14.9) million, or ($1.02) per share, in 2022. Net loss also included $18.1 million, or ($1.23) per share, for charges associated with product rationalization, acquisition related amortization, discontinuation of software development, Parcus arbitration settlement and shareholder activism. Adjusted net loss 1 for the year was ($4.3) million, or ($0.30) per share, compared to adjus","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001322/0001171843-24-001322-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$166.7 million"},{"label":"Net income","value":"($82.7) million"},{"label":"EPS","value":"($5.64) per share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c82dd2263f143057f25385cdda21c1f440beb838","claim":"Anika Therapeutics, Inc. reported fourth quarter ended December 31, 2023 results: revenue $43.0 million, net income ($63.0) million, EPS ($4.30) per share. Guidance initiated.","evidence_excerpt":"Revenue in the fourth quarter of 2023 was $43.0 million, up 8% compared to $39.6 million in the fourth quarter of 2022. OA Pain Management revenue of $25.1 million, up 12%, on growing global commercial adoption and some order timing Joint Preservation and Restoration revenue of $15.3 million, up 7% Non-Orthopedic revenue of $2.6 million, down 8% Gross margin was 61%, including $1.6 million of non-cash acquisition-related intangible asset amortization; Adjusted gross margin 1 was 65%. Recorded a non-recurring, non-cash impairment charge in the fourth quarter of $62.2 million for the intangible assets associated with the Q1-2020 acquisitions of Arthrosurface and Parcus Medical. Including the non-cash impairment charge, net loss was ($63.0) million, or ($4.30) per share, compared to net loss of ($4.9) million, or ($0.34) per share, in the prior year period. Adjusted net income 1 was $0.8 million, or $0.05 per diluted share, compared to adjusted net loss 1 of ($3.0) million, or ($0.21) per","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001322/0001171843-24-001322-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$43.0 million"},{"label":"Net income","value":"($63.0) million"},{"label":"EPS","value":"($4.30) per share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}